Navigation Links
EmSense Raises $9 Million Series C Round of Financing
Date:11/3/2009

SAN FRANCISCO, Nov. 3 /PRNewswire/ -- EmSense Corporation, the company that created the first scalable physiological and brainwave measurement technology, today announced the completion of a $9 Million Series C round of funding, led by an investment from Technology Partners with existing investor the Foundry Group also participating.

This funding will allow EmSense to continue its global expansion in support of its many market research partners. The funds will also enable the company to develop a large bio-sensory in-home panel - the first of its kind.

"We believe that neuromarketing is now mainstream and is poised for explosive growth. Over the past year we conducted extensive diligence on the neuromarketing space and chose EmSense based on their highly-scalable business model, numerous clients, and key market research partners," said Roger Quy, general partner with Technology Partners.

"We are especially pleased to welcome Technology Partners as well-respected investors and valued partners as EmSense enters a period of very rapid growth. Roger Quy may be one of the only venture capitalists with a PhD in neuroscience and a research background in neurotechnology; and, as such, is particularly well suited to advise our company. This is yet another endorsement of our science, technology, and business model," said Keith Winter, president & CEO of EmSense. "We are also very happy to have Foundry Group's continued support in this round."

"Foundry Group is very excited to complete a follow-on investment in what we see as the dominant player in the rapidly expanding neuromarketing industry. Furthermore, EmSense represents a key company in our human-computer interaction investment theme, which focuses on the ongoing evolution in the way humans interact with their computing devices - well beyond the keyboard and mouse, " said Ryan McIntyre, managing director at Foundry Group and EmSense board member.

About EmSense

EmSense is a leading-edge neuroscience company that applies advances in EEG and other neurometrics to provide clients with deep and reliable understanding of consumers' emotional and cognitive engagement with marketing stimuli. The company's quantitative metrics deliver breakthrough insights that facilitate the creation and optimization of advertising, packaging, media content, online marketing, and both the live in-store and virtual store shopping experiences. EmSense provides expertise and advancements in emotion tracking, cognitive neuroscience, analytics, and market research through their proprietary EmGear(TM), the first ever dry, wireless, scalable, non-invasive EEG neuroscience technology. EmSense is headquartered in San Francisco. To learn more about EmSense's technology solutions and consulting services, visit www.emsense.com.

About Technology Partners

Founded 25 years ago, Technology Partners manages a total of approximately $700 million of venture capital and is currently investing from Technology Partners VIII, a 2007 fund. Investments are targeted in the areas of cleantech and life science, with a particular focus in neurotechnology and consumer medicine.

About Foundry Group

Foundry Group is a venture capital firm focused on making investments in early-stage information technology, Internet, and software startups. Foundry Group's current venture fund of $225m was launched in late 2007. The firm is located in Boulder, Colorado, and invests throughout North America.

SOURCE EmSense Corporation


'/>"/>
SOURCE EmSense Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology news :

1. PRS And EmSense Partner To Integrate Bio-Sensory Measures In Packaging Research Studies
2. New research on structure of bones raises questions for treatment of osteoporosis
3. New population of Iberian lynx raises hope, says World Wildlife Fund
4. New study raises concerns about proposed mitigation strategy for marine bycatch
5. Argyrin: Natural substance raises hope for new cancer therapies
6. OSU study shows exposure to bad air raises blood pressure
7. Similar survival rates for Pacific salmon in Fraser, Columbia Rivers raises new questions
8. Repeat C-section before 39 weeks raises risk of neonatal illness
9. Discovery raises new doubts about dinosaur-bird links
10. Structure of 450 million year old protein reveals evolutions steps
11. First orchid fossil puts showy blooms at some 80 million years old
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2016)... 2016   Acuant , the leading ... has partnered with RightCrowd ® to ... Management, Self-Service Kiosks and Continuous Workforce Assurance. ... functional enhancements to existing physical access control ... with an automated ID verification and authentication ...
(Date:6/20/2016)... -- Securus Technologies, a leading provider of civil ... investigation, corrections and monitoring announced that after exhaustive ... the final acceptance by all three (3) Department ... (MAS) installed. Furthermore, Securus will have contracts for ... October, 2016. MAS distinguishes between legitimate wireless device ...
(Date:6/9/2016)...  Perkotek an innovation leader in attendance control systems is proud to announce the ... employers to make sure the right employees are actually signing in, and to even ... ... ... ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... Raleigh, NC (PRWEB) , ... June 27, 2016 ... ... a mission to bring innovative medical technologies, services and solutions to the healthcare ... development and implementation of various distribution, manufacturing, sales and marketing strategies that are ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)...   Boston Biomedical , an industry leader ... target cancer stemness pathways, announced that its lead ... Designation from the U.S. Food and Drug Administration ... gastroesophageal junction (GEJ) cancer. Napabucasin is an orally ... stemness pathways by targeting STAT3, and is currently ...
(Date:6/23/2016)... Cancer Foundation (PCF) is pleased to announce 24 new Young Investigator (YI) ... of the Class of 2016 were selected from a pool of 128 applicants ... the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology: